In contrast, TP group seems to have a higher positive rates of biopsy cores among the patients with T1 and T2 stages (30.6% vs 36.9%, OR: 0.754, p = 0.029), and the literature also reported the advantage of the TP approach in patients with PSA levels of 4.01–10.00 ng/mL [6, 27], indicating that TP approach may have advantage in patients with low- and intermediate-risk prostate cancer. Here, KLK3 is linked to prostate carcinoma.